Navigation Links
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Date:6/9/2009

product candidates in development, and Nektar's collaborations with third parties. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's proprietary product candidates and those of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval; (ii) Nektar or its partners may not be able to successfully obtain regulatory approval for product candidates in development; (iii) Nektar's commercialization partners may not be successful in their sales and marketing efforts even if current product candidates successfully receive future regulatory approval in one or more markets; (iv) Nektar's patent applications for its technology platforms and proprietary or partner product candidates may not issue, patents that have issued may not be enforceable; and or intellectual property licenses from third parties may be required in the future; and (v) other important risks and uncertainties set forth in Nektar's most recent Quarterly Report on Form 10-Q filed on May 8, 2009 and its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

For more information on Nektar Therapeutics, please visit www.nektar.com

Jennifer Ruddock, 650-631-4954


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Nektar Therapeutics Reports First Quarter 2009 Financial Results
2. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
5. Nektar Announces Retirement of Irwin Lerner from Board of Directors
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... China Sky One,Medical, Inc. ("China Sky One Medical" ... fully integrated pharmaceutical company developing and producing,over-the-counter drugs ... that the Company has 30 medicines that will ... Basic Medical Insurance, Industrial Injury Insurance,and Maternity Insurance ... 30 medicines treat a variety of common ailments ...
(Date:12/15/2009)... Va., Dec. 15 AstraZeneca (NYSE: ... of Virginia (UVa) in Charlottesville, today announced ... research collaboration to enhance development of new ... with a secondary focus on peripheral vascular ... ) ,, The collaborative preclinical research projects ...
(Date:12/15/2009)... N.Y., Dec. 15 The International Society ... the professional society is continuing to accept abstracts ... held in Arlington, VA, April 19-21, 2010. This ... encouraging non-members to join the organization to submit ... submission deadline is 12 AM EST, January 15, ...
(Date:12/15/2009)... and LONDON, Dec. 15 ... Thomson Pharma ® has become the first drug ... protocol and outcome information. This highly anticipated new ... customers this month. ,, Thomson ... intelligence from registries, publications, press releases, conferences, and ...
Breaking Biology Technology:China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2
... long ago as 1988, I enthusiastically embraced the idea that ... create magazines to examine and celebrate that life. Both times, ... time. , ,Now, many years later, I'm getting very excited ... digital lifestyle. This time, though, the market conditions are fundamentally ...
... Third Wave Technologies has announced the launch ... In conjunction with Invaders premiere, the company announced a ... non-profit health plan in the United States, to supply ... customer, said Rod Hise, director, corporate communications of Third ...
... ideas and small microchips. , ,In dictionary terms, it ... and high technology. In real-life terms, it means that I ... end up in my basement aside X.10 cameras, a commercial-strength ... video games and a pile of last years gadgets de ...
Other Biology Technology:Digital Lifestyle: I'm linked in, now what? 2Digital Lifestyle: I'm linked in, now what? 3Digital Lifestyle: I'm linked in, now what? 4Third Wave strikes deal with Kaiser Permanente on cystic fibrosis reagents 2Three mainstream technologies you should not ignore 2
(Date:12/16/2009)... LONDON, Dec. 16 European Union ... protecting their borders, which are increasingly subjected ... High investment in advanced technology security and ... market. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, ... http://www.aerospace.frost.com ), Border Security Market Assessment ...
(Date:12/15/2009)... COLUMBIA, Mo. As soon as babies are ... as jaundice and e-coli. For up to a month, ... Although these infections are often minor, they can lead ... newborns, immune systems, University of Missouri researchers have pinpointed ... lead to an immune-strengthening vaccine. , "We,re trying to ...
(Date:12/15/2009)... agreement with the British Society for Research on Ageing ... Biogerontology for an initial period of three ... the Biogerontology editorial board and will acquire ... sponsor the society and provide society members with free ... . , Biogerontology offers a platform for ...
Breaking Biology News(10 mins):Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 1Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 2Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 3University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 1University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 2University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 1Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 2Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 4Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 5Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 7Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 8Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 9Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 10Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 11Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 12
... As the Arctic Ocean warms this century, shellfish, snails ... an invasion of the northern Atlantic that was interrupted ... Vermeij, professor of geology at the University of California, ... Sciences. , Climate models predict a nearly ice-free Arctic ...
... University of Texas Health Science Center at Houston have ... to determine whether gluten and dairy products play a ... The pilot study is one of seven current studies ... Department of Psychiatry and Behavioral Sciences at The University ...
... 07 August 2008 - "Big things come in ... more true when discussing the mouse. This little ... through its contributions in understanding human genetics and disease. ... (DMM), http://dmm.biologists.org , genetics researchers from Yale University ...
Other Biology News:Pacific shellfish ready to invade Atlantic 2UT Health Science Center researchers study diet and autism 2
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Biology Products: